One research focus in our group is to generate innovative therapeutic agents. In this sense, we have obtained antigen specific fully human monoclonal antibodies (huMoAb) using genetically engineered mice and hybridoma technology.

Particularly, we could highlight:

  • BH1, a huMoAb that recognizes the molecule HLA-class II.  BH1 could be a good candidate as a therapeutic agent for the treatment of different HLA-class II positive leukaemias and other malignancies.
  • h-AIM29, this huMoAb is specific for the human CD69 molecule. Some of its potential clinical application is for patients with arthritis or even with those with cancer.
  • Several huMoAb directed to human B and monocytes cells.


Projects in this research line:

Your Portfolio Archive currently has no entries. You can start creating them on your dashboard.